Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril 2008 Sep;90(3):872-5
Date
12/25/2007Pubmed ID
18155704DOI
10.1016/j.fertnstert.2007.01.046Scopus ID
2-s2.0-51449094458 (requires institutional sign-in at Scopus site) 19 CitationsAbstract
The effect of mifepristone on the expression of secretory leukocyte protease inhibitor (SLPI) in the endometrium of women using depot medroxyprogesterone acetate (DMPA) was investigated in this randomized, placebo-controlled trial. The study showed that the administration of DMPA led to a substantial inhibition of endometrial SLPI protein and mRNA, and that the addition of mifepristone to DMPA-exposed endometrium partially restored the expression of glandular SLPI.
Author List
Li A, Felix JC, Yang W, Jain JKAuthor
Juan Felix MD Vice Chair, Director, Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultContraceptive Agents, Female
Contraceptives, Oral, Synthetic
Drug Interactions
Endometrium
Female
Gene Expression
Humans
Medroxyprogesterone Acetate
Mifepristone
Placebo Effect
Secretory Leukocyte Peptidase Inhibitor